The biology of combination immunotherapy in recurrent metastatic head and neck cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The biology of combination immunotherapy in recurrent metastatic head and neck cancer
Authors
Keywords
Head and neck cancer, Immunotherapy, Immune escape, Immunotherapy combination
Journal
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
Volume 136, Issue -, Pages 106002
Publisher
Elsevier BV
Online
2021-05-05
DOI
10.1016/j.biocel.2021.106002
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Regulation of PD-L1 expression in the tumor microenvironment
- (2021) Ming Yi et al. Journal of Hematology & Oncology
- Tumor microenvironment and immune-related therapies of Head and neck squamous cell carcinoma
- (2021) Yixiao Qin et al. Molecular Therapy-Oncolytics
- Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
- (2020) Matthew H. Taylor et al. JOURNAL OF CLINICAL ONCOLOGY
- Involvement of TGF-β and ROS in G1 Cell Cycle Arrest Induced by Titanium Dioxide Nanoparticles Under UVA Irradiation in a 3D Spheroid Model
- (2020) Yuanyuan Ren et al. International Journal of Nanomedicine
- The role of cancer-derived microRNAs in cancer immune escape
- (2020) Ming Yi et al. Journal of Hematology & Oncology
- Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy
- (2020) Reza Aimohammadi et al. International Journal of Nanomedicine
- Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer
- (2020) Wei Liu et al. OncoTargets and Therapy
- The 5-Ws of immunotherapy in head and neck cancer
- (2020) Andrea Botticelli et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers
- (2020) Ying Jiao et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer
- (2020) Panagiota Economopoulou et al. Cancers
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck
- (2019) Elie El Rassy et al. Future Oncology
- Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma
- (2019) Jacob H. Rasmussen et al. BRITISH JOURNAL OF CANCER
- EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
- (2019) Lisa F. Licitra et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety of radiotherapy with concurrent and adjuvant MEDI4736 (durvalumab) in patients with locoregionally advanced head and neck cancer with a contraindication to cisplatin: NRG-HN004.
- (2019) Loren K. Mell et al. JOURNAL OF CLINICAL ONCOLOGY
- Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
- (2019) Ming Yi et al. Molecular Cancer
- Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response
- (2019) Rajarsi Mandal et al. SCIENCE
- Competition for nutrients and its role in controlling immune responses
- (2019) Nidhi Kedia-Mehta et al. Nature Communications
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
- (2019) Ezra E. W. Cohen et al. Journal for ImmunoTherapy of Cancer
- Prospects for combining immune checkpoint blockade with PARP inhibition
- (2019) Anping Li et al. Journal of Hematology & Oncology
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
- (2019) Shengnan Yu et al. Molecular Cancer
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma
- (2019) Daniel L. Faden et al. ORAL ONCOLOGY
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
- (2019) Shuang Qin et al. Molecular Cancer
- Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor
- (2019) Xianguang Bai et al. OncoTargets and Therapy
- Gut microbiome modulates efficacy of immune checkpoint inhibitors
- (2018) Ming Yi et al. Journal of Hematology & Oncology
- Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
- (2018) Yan Lan et al. Science Translational Medicine
- Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
- (2018) Tara C. Mitchell et al. JOURNAL OF CLINICAL ONCOLOGY
- Regression of epithelial cancers in humans following t-cell receptor gene therapy targeting human papillomavirus-16 E7.
- (2018) Nisha Nagarsheth et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with HPV associated cancers.
- (2018) Julius Strauss et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck.
- (2018) Khalil Saleh et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
- (2018) Ming Yi et al. Molecular Cancer
- Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer
- (2018) Erminia Massarelli et al. JAMA Oncology
- Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy
- (2018) Y -P Chen et al. ANNALS OF ONCOLOGY
- Regulatory T cells expressing abundant CTLA‐4 on the cell surface with a proliferative gene profile are key features of human head and neck cancer
- (2018) Takuma Matoba et al. INTERNATIONAL JOURNAL OF CANCER
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- (2018) Ezra E W Cohen et al. LANCET
- Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC
- (2018) Lillian L. Siu et al. JAMA Oncology
- Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
- (2018) Takefumi Komiya et al. Frontiers in Oncology
- Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
- (2017) Joshua Bauml et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric antigen receptor T cells: a novel therapy for solid tumors
- (2017) Shengnan Yu et al. Journal of Hematology & Oncology
- Radiotherapy and immunotherapy: a beneficial liaison?
- (2017) Ralph R. Weichselbaum et al. Nature Reviews Clinical Oncology
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma
- (2017) Ayman Oweida et al. OncoImmunology
- PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy
- (2017) Dawn E. Dolan et al. Cancer Control
- CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer
- (2016) Raghvendra M. Srivastava et al. CLINICAL CANCER RESEARCH
- Exosomes and tumor-mediated immune suppression
- (2016) Theresa L. Whiteside JOURNAL OF CLINICAL INVESTIGATION
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment
- (2016) Shanthi Marur et al. MAYO CLINIC PROCEEDINGS
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer
- (2016) Ruth J. Davis et al. ORAL ONCOLOGY
- Tumor microenvironment: Sanctuary of the devil
- (2015) Lanlan Hui et al. CANCER LETTERS
- TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity
- (2015) Claire Vanpouille-Box et al. CANCER RESEARCH
- Immunology and Immunotherapy of Head and Neck Cancer
- (2015) Robert L. Ferris JOURNAL OF CLINICAL ONCOLOGY
- Myeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacy
- (2015) Oana Draghiciu et al. OncoImmunology
- HIF-α/MIF and NF-κB/IL-6 Axes Contribute to the Recruitment of CD11b+Gr-1+ Myeloid Cells in Hypoxic Microenvironment of HNSCC
- (2015) Guiquan Zhu et al. NEOPLASIA
- Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
- (2013) S. Lyford-Pike et al. CANCER RESEARCH
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
- (2011) Lukas Baitsch et al. JOURNAL OF CLINICAL INVESTIGATION
- Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy
- (2010) Kazuki Yamasaki et al. CLINICAL IMMUNOLOGY
- Combination therapy ofin vitro-expanded natural killer T cells and α-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma
- (2009) Naoki Kunii et al. CANCER SCIENCE
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients
- (2009) Jean-Pierre Pignon et al. RADIOTHERAPY AND ONCOLOGY
- T Regulatory Type 1 Cells in Squamous Cell Carcinoma of the Head and Neck: Mechanisms of Suppression and Expansion in Advanced Disease
- (2008) C. Bergmann et al. CLINICAL CANCER RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started